These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 28303694)

  • 1. Lutetium
    Emmett L; Willowson K; Violet J; Shin J; Blanksby A; Lee J
    J Med Radiat Sci; 2017 Mar; 64(1):52-60. PubMed ID: 28303694
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
    J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
    Ferdinandus J; Violet J; Sandhu S; Hofman MS
    Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EANM procedure guidelines for radionuclide therapy with
    Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.
    Naik M; Khan SR; Lewington V; Challapalli A; Eccles A; Barwick TD
    Br J Radiol; 2024 Aug; 97(1160):1391-1404. PubMed ID: 38733571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSMA-targeted radioligand therapy in prostate cancer].
    Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
    Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
    Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer.
    Huangfu Z; Yang J; Sun J; Xu B; Tao L; Wu J; Wang F; Wang G; Meng F; Zhong Z
    J Control Release; 2024 Nov; 375():767-775. PubMed ID: 39332777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID;
    Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
    Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
    BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses.
    Al-Rashdan R; Al-Abdallat H; Sathekge MM; Mirzaei S; Shahait M; Al-Khawaldeh K; Abdlkadir AS; Lee S; Al-Ibraheem A
    Nuklearmedizin; 2024 Jun; 63(3):188-198. PubMed ID: 38262473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of [
    Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
    Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
    Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.